论文部分内容阅读
目的探讨外周血差异显示编码3(DD3)mRNA定量检测在前列腺癌诊断和治疗监测中意义。方法用荧光定量逆转录聚合酶链反应(FQ-RT-PCR)方法对35例未治疗前列腺癌、58例内分泌治疗后前列腺癌、59例良性前列腺增生患者和10例健康男性志愿者外周血DD3mRNA含量进行定量检测,并对DD3mRNA诊断及疗效监测价值进行评价。结果未治疗前列腺癌组外周血DD3mRNA含量明显高于治疗后前列腺癌组、前列腺增生组和健康男性志愿者组,差异具有统计学意义(P<0.01)。未治疗前列腺癌患者随着临床分期增加,外周血DD3mRNA含量也增高,差异具有统计学意义(P<0.01)。当临界值为846拷贝/ml时,DD3mRNA曲线下面积为0.822(95%CI:0.725~0.919),灵敏度、特异度分别为74.3%、89.8%。结论外周血DD3mRNA定量检测是前列腺癌诊断的良好指标,可作为内分泌治疗过程疗效监测的指标。
Objective To investigate the significance of quantitative detection of DD3 mRNA in peripheral blood in the diagnosis and treatment of prostate cancer. Methods The expression of DD3 mRNA in peripheral blood of 35 cases of untreated prostate cancer, 58 cases of endocrine-treated prostate cancer, 59 cases of benign prostatic hyperplasia and 10 healthy male volunteers were detected by fluorescence quantitative reverse transcription polymerase chain reaction (FQ-RT-PCR) Content of quantitative detection, and DD3mRNA diagnosis and efficacy monitoring value evaluation. Results The level of DD3 mRNA in peripheral blood of untreated prostate cancer patients was significantly higher than that of the prostate cancer patients, benign prostatic hyperplasia patients and healthy male volunteers after treatment. The difference was statistically significant (P <0.01). Untreated prostate cancer patients with clinical stage increased, peripheral blood DD3mRNA content also increased, the difference was statistically significant (P <0.01). When the cut-off value was 846 copies / ml, the area under the curve of DD3 mRNA was 0.822 (95% CI: 0.725-0.919). The sensitivity and specificity were 74.3% and 89.8% respectively. Conclusion Quantitative detection of DD3 mRNA in peripheral blood is a good indicator of the diagnosis of prostate cancer and can be used as an indicator of curative effect monitoring of endocrine therapy.